U.S. markets close in 6 hours 19 minutes
  • S&P 500

    4,148.50
    -31.26 (-0.75%)
     
  • Dow 30

    33,969.09
    -84.85 (-0.25%)
     
  • Nasdaq

    12,053.80
    -147.02 (-1.20%)
     
  • Russell 2000

    2,001.22
    +40.41 (+2.06%)
     
  • Crude Oil

    76.05
    +0.17 (+0.22%)
     
  • Gold

    1,893.20
    -37.60 (-1.95%)
     
  • Silver

    22.68
    -0.93 (-3.94%)
     
  • EUR/USD

    1.0864
    -0.0047 (-0.43%)
     
  • 10-Yr Bond

    3.5140
    +0.1180 (+3.47%)
     
  • GBP/USD

    1.2140
    -0.0089 (-0.73%)
     
  • USD/JPY

    130.2700
    +1.6660 (+1.30%)
     
  • BTC-USD

    23,383.78
    -503.15 (-2.11%)
     
  • CMC Crypto 200

    534.07
    -2.79 (-0.52%)
     
  • FTSE 100

    7,858.02
    +37.86 (+0.48%)
     
  • Nikkei 225

    27,509.46
    +107.41 (+0.39%)
     

RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate

  • The United States Patent and Trademark Office (USPTO) granted a further method of use patent for RedHill Biopharma Ltd's (NASDAQ: RDHL) COVID-19 treatment, opaganib.

  • The move grants a new method of use patent to inhibit COVID-19 in patients with pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%.

  • The new patent, expiring in 2041, protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia.

  • Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.

  • In the analysis of 251 participants requiring a FiO2 up to and including 60% at baseline (54% of study participants), oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation.

  • Late-stage development of opaganib is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.

  • Price Action: RDHL shares are up 50.90% at $0.70 on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.